Scarica l'app Stockscreener
3.33
6.46%
-0.23
Dopo l'orario di chiusura:
3.31
-0.02
-0.60%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IOVA Giù?
Forum
Previsione
Frazionamento azionario
Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie
Cell Therapy Veteran With 16 Successful Launches Joins TScan Leadership - Stock Titan
Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) The Top Penny Stock That Will Skyrocket? - Insider Monkey
1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street - MSN
3 Growth Stocks Wall Street Might Be Sleeping On -- But I'm Not - The Motley Fool
Iovance Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4) - MarketScreener
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Iovance Expands Team: 308,710 Stock Options Awarded as Growth Accelerates - StockTitan
Iovance: The Company Makes It Hard To Estimate Revenue Growth (NASDAQ:IOVA) - Seeking Alpha
Philly weekly roundup: Iovance Biotherapeutics expands; Jawnt-SpotHero partnership; Mayor's budget address - Technical.ly
Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) the Most Oversold Penny Stocks to Buy According to Analysts? - Insider Monkey
Stifel maintains Buy on Iovance Biotherapeutics stock, $18 target By Investing.com - Investing.com Canada
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up? - Yahoo
Melanoma Therapeutics Market to Reach $ 8.35 Bn by 2032Key - openPR
Proficio Capital Partners LLC Acquires New Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
SBI Securities Co. Ltd. Acquires New Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today - AOL
Can Amtagvi Drive IOVA's Return To Glory - RTTNews
IOVA stock touches 52-week low at $3.62 amid market challenges - Investing.com
Iovance Biotherapeutics Inc to Host Earnings Call - ACCESS Newswire
Iovance Biotherapeutics (NASDAQ:IOVA) Given New $19.00 Price Target at The Goldman Sachs Group - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 5.8% After Analyst Downgrade - Defense World
Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Dips 27% Despite Reaffirmed 2025 Earnings Guidance - Yahoo Finance
Iovance Biotherapeutics price target lowered to $30 from $34 at Chardan - Yahoo Finance
Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Cut to $19.00 by Analysts at The Goldman Sachs Group - Defense World
Chardan Cuts Price Target on Iovance Biotherapeutics to $30 From $34, Keeps Buy Rating - Marketscreener.com
Rhumbline Advisers Has $2.86 Million Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
Iovance Biotherapeutics’ (IOVA) “Buy” Rating Reiterated at HC Wainwright - Defense World
Research Analysts Set Expectations for IOVA Q1 Earnings - Defense World
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported Earnings, And Analysts Cut Their Target Price - simplywall.st
Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 12-Month Low After Analyst Downgrade - Defense World
Iovance Biotherapeutics (NASDAQ:IOVA) Given "Buy" Rating at HC Wainwright - MarketBeat
Iovance Biotherapeutics Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance UK
Robert W. Baird Cuts Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $20.00 - MarketBeat
Iovance Biotherapeutics Target of Unusually Large Options Trading (NASDAQ:IOVA) - Defense World
Iovance down 18% warning it could be impacted by geopolitical instability, inflation - MSN
Iovance Biotherapeutics (NASDAQ:IOVA) Releases Earnings Results, Hits Expectations - MarketBeat
Iovance Biotherapeutics’ Earnings Call Highlights Growth and Challenges - TipRanks
Iovance Biotherapeutics (NASDAQ:IOVA) Announces Quarterly Earnings Results, Meets Estimates - MarketBeat
New York State Common Retirement Fund Sells 98,840 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Forecasting The Future: 4 Analyst Projections For Iovance Biotherapeutics - Benzinga
Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade) - Seeking Alpha
Truist Adjusts Price Target on Iovance Biotherapeutics to $15 From $25, Maintains Buy Rating - Marketscreener.com
IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty - Yahoo Finance
IOVA stock touches 52-week low at $3.92 amid market challenges By Investing.com - Investing.com South Africa
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2024 Earnings Call Transcript - Insider Monkey
Iovance Biotherapeutics Q4 Loss Narrows, Revenue Rises -February 28, 2025 at 03:51 am EST - Marketscreener.com
Iovance Biotherapeutics Inc (IOVA) Q4 2024 Earnings Call Highlig - GuruFocus
Iovance Biotherapeutics Inc (IOVA) Q4 2024 Earnings Call Highlights: Strong Revenue and ... - Yahoo Finance
Iovance Biotherapeutics: Q4 Earnings Snapshot - The Washington Post
Iovance Biotherapeutics Reports Strong 2024 Earnings - TipRanks
Earnings call transcript: Iovance Biotherapeutics Q4 2024 results miss revenue forecasts - Investing.com India
Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Iovance Biotherapeutics reports Q4 EPS (26c), consensus (27c) - TipRanks
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Iovance Biotherapeutics (IOVA) Projected to Post Earnings on Thursday - MarketBeat
IOVANCE BIOTHERAPEUTICS, INC. SEC 10-K Report - TradingView
1.05%
1.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):